OBJECTIVES: To investigate the relationship of other body mass index (BMI) ranges with Homeostasis Model Assessment-Insulin Resistance (HOMA-IR), a surrogate marker for insulin resistance in adolescents. STUDY DESIGN: Cross-sectional analysis of a nationally representative sample of 1837 nondiabetic, nonpregnant 12 to 19 year old persons from the National Health and Nutrition Examination Survey, 1999-2002. The main outcome measurement of insulin resistance was calculated as HOMA-IR > 3.16. RESULTS: Having a BMI > or = 75th percentile is associated with a high HOMA-IR levels. As the BMI percentile increases, the odds of high HOMA-IR levels increase (BMI percentile 75-84.9, OR 4.277, 95% CI 2.090-8.752; BMI percentile 85-94.9, OR 4.299, 95% CI 2.158-8.563; BMI > or = 95th percentile, OR 17.907, 95% CI 11.360-28.228). CONCLUSION: Adolescents with BMI percentile of 75 to 84.9, which represents approximately 1.2 million US adolescents, have not previously been identified as having higher HOMA-IR levels.
OBJECTIVES: To investigate the relationship of other body mass index (BMI) ranges with Homeostasis Model Assessment-Insulin Resistance (HOMA-IR), a surrogate marker for insulin resistance in adolescents. STUDY DESIGN: Cross-sectional analysis of a nationally representative sample of 1837 nondiabetic, nonpregnant 12 to 19 year old persons from the National Health and Nutrition Examination Survey, 1999-2002. The main outcome measurement of insulin resistance was calculated as HOMA-IR > 3.16. RESULTS: Having a BMI > or = 75th percentile is associated with a high HOMA-IR levels. As the BMI percentile increases, the odds of high HOMA-IR levels increase (BMI percentile 75-84.9, OR 4.277, 95% CI 2.090-8.752; BMI percentile 85-94.9, OR 4.299, 95% CI 2.158-8.563; BMI > or = 95th percentile, OR 17.907, 95% CI 11.360-28.228). CONCLUSION: Adolescents with BMI percentile of 75 to 84.9, which represents approximately 1.2 million US adolescents, have not previously been identified as having higher HOMA-IR levels.
Authors: Mimi S Kim; Anna Ryabets-Lienhard; Anh Dao-Tran; Steven D Mittelman; Vicente Gilsanz; Sheree M Schrager; Mitchell E Geffner Journal: J Clin Endocrinol Metab Date: 2015-06-10 Impact factor: 5.958
Authors: Gabriela P Finkielstain; Mimi S Kim; Ninet Sinaii; Miki Nishitani; Carol Van Ryzin; Suvimol C Hill; James C Reynolds; Reem M Hanna; Deborah P Merke Journal: J Clin Endocrinol Metab Date: 2012-09-18 Impact factor: 5.958
Authors: Irena Aldhoon-Hainerová; Hana Zamrazilová; Lenka Dušátková; Barbora Sedláčková; Petr Hlavatý; Martin Hill; Richard Hampl; Marie Kunešová; Vojtěch Hainer Journal: Diabetol Metab Syndr Date: 2014-09-16 Impact factor: 3.320